Management — Initial therapy / Multimodality therapy
• Novel agent with prior nonrefractory exposure and CNS penetration: IMiDs (pomalidomide, lenalidomide, thalidomide), venetoclax for t(11;14) ± • Intrathecal methotrexate/cytarabine ± steroid • Intrathecal thiotepa/steroid • Radiation therapy • Evaluation for BCMA CAR T-cell therapy if not previously received • Palliative care consultation